HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

Benzinga Newsdesk www.benzinga.com Positive 56.5%

Neg 0% Neu 0% Pos 56.5%

HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.